Neurology

Biomedical/pharma, Neurology

September 22, 2021

Biogen’s controversial Alzheimer’s drug approved by the FDA – what now?

for V-Bio Ventures

June 22, 2021

Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy

for BioVox

April 28, 2021

To fund or not to fund: the psychology of investment decisions

for V-Bio Ventures

March 31, 2021

Augustine Therapeutics developing new medicines for neuromuscular diseases

for BioVox

March 23, 2021

Augustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases

for BioVox

March 19, 2021

Augustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board

for BioVox

March 18, 2021

Augustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases

for BioVox

January 27, 2021

Prestigious prize for Belgian breakthrough in brain research

for BioVox

December 16, 2020

Decades-old discoveries cause paradigm shifts in modern medicine

for V-Bio Ventures

August 31, 2020

A novel approach to neurology could bring relief to people in pain

for V-Bio Ventures

August 31, 2020

Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures

for V-Bio Ventures

November 26, 2019

Magic mushrooms in modern medicine

for V-Bio Ventures

March 4, 2019

Orphan CNS diseases receive attention with new Minoryx site in Belgium

for BioVox

February 19, 2019

Microbiome linked to depression in a groundbreaking Benelux study

for BioVox

January 11, 2018

Rewind Therapeutics secures funding for Multiple Sclerosis research

for BioVox